Dosing Schedule

Recommended dosing schedule for RYBREVANT® + chemotherapy1

RYBREVANT® Faspro chemo chartRYBREVANT® Faspro chemo chart

*Dose adjustments not required for subsequent body weight changes.

†This refers only to RYBREVANT® and pemetrexed. Carboplatin should only be administered every 3 weeks for up to 12 weeks.

The recommended dosage of RYBREVANT® is based on baseline body weight and can be administered as an intravenous infusion after dilution.1

With chemotherapy

Administer the regimen in the following order: pemetrexed first, carboplatin second, and RYBREVANT® last.​

Refer to the full Prescribing Information for pemetrexed and carboplatin for the respective dosing information.

For additional dosage and administration guidance for RYBREVANT® (including as a single agent), please see the full Prescribing Information.

See Proactive Therapy Management to help reduce the risk of key ARs

Learn more

In both the MARIPOSA-2 and PAPILLON trials, infusion times decreased over time with RYBREVANT®2

MARIPOSA-2 clinical trial median infusion times by hours*

RYBREVANT® Faspro chemo chartRYBREVANT® Faspro chemo chart

PAPILLON clinical trial median infusion times by hours†

RYBREVANT® Faspro chemo chartRYBREVANT® Faspro chemo chart

Total infusion time is approximately 4 to 6 hours for Day 1 and 6 to 8 hours for Day 2. Day 2 chair time is longer because of increased dose from Day 1. Subsequent infusion time is approximately 2 hours.1

*Data reflect results from 3-week dosing in the MARIPOSA-2 trial.2

†Data reflect results from 3-week dosing in the PAPILLON trial.2

AR, adverse reaction; AUC, area under the curve; Q3W, once every 3 weeks.

Preparation

Preparation for RYBREVANT®1

Dilute and prepare RYBREVANT® for intravenous infusion before administration

RYBREVANT® Faspro chemo chartRYBREVANT® Faspro chemo chart

PE, polyethylene; PP, polypropylene; PVC, polyvinylchloride.

Administration

Administration for RYBREVANT®1

  • Administer the diluted solution by intravenous infusion using an infusion set fitted with a flow regulator and with an in-line, sterile, non-pyrogenic, low protein-binding PES filter (pore size 0.2 micrometer)
  • Administration sets must be made of PU, PBD, PVC, PP, or PE
  • The administration set with filter must be primed with either 5% dextrose injection or 0.9% sodium chloride injection prior to the initiation of each RYBREVANT® infusion
  • Do not infuse RYBREVANT® concomitantly in the same intravenous line with other agents

RYBREVANT® in combination with carboplatin and pemetrexed1

  • Administer RYBREVANT® in combination with carboplatin and pemetrexed infusions every 3 weeks intravenously until disease progression or unacceptable toxicity according to the infusion rates
  • Administer RYBREVANT® via a peripheral line on Week 1 and Week 2 to reduce the risk of IRRs during initial treatment
  • RYBREVANT® may be administered via a central line for subsequent weeks
  • For the initial infusion, prepare RYBREVANT® as close to administration time as possible to allow for the possibility of extended infusion time in the event of an IRR
  • Administer the pemetrexed infusion first, carboplatin infusion second, and the RYBREVANT® infusion last

IRR, infusion-related reaction; PBD, polybutadiene; PES, polyethersulfone; PU, polyurethane.

RYBREVANT® (amivantamab) with carboplatin and pemetrexed dosing and administration breakdown over timeRYBREVANT® (amivantamab) and LAZCLUZE™ dosing and administration breakdown over time

*In the absence of IRRs, increase the initial infusion rate to the subsequent infusion rate after 2 hours based on patient tolerance. Total infusion time is approximately 4 to 6 hours for Day 1 and 6 to 8 hours for Day 2. Subsequent infusion time is approximately 2 hours.

References:

  1. RYBREVANT® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
  2. Data on file. Janssen Biotech, Inc.